Dextromethorphan augmentation therapy for obsessive compulsive disorder
- Conditions
- obsessive compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT20221227056943N1
- Lead Sponsor
- Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 54
Patients diagnosed with obsessive-compulsive disorder with moderate to high severity (YBOCS>16)
Patients who have not responded to 12 weeks of obsessive-compulsive disorder treatment with an adequate dose of an SSRI
People over 18 years old
People who have filled out informed consent
Comorbidity with other psychiatric disorders except major depressive disorder, including psychotic disorders, substance dependence disorders
Pregnancy
Severe kidney and liver disease
Unstable medical condition
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of Obsessive Compulsive Disorder based on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Timepoint: Yale-Brown obsessive compulsive scale (Y-BOCS) was measured at the beginning of the study and 30 and 90 days after the start of treatment. Method of measurement: Yale-Brown obsessive compulsive scale (Y-BOCS) Questionnaire.
- Secondary Outcome Measures
Name Time Method